Combined detection of estrogen and tumor markers is an important reference factor in the diagnosis and prognosis of lung cancer

The correlation between lung cancer tumor markers and sex differences in lung cancer remains a clinical problem that is worthy of further study. This study investigated the significance of the combined detection of 17β‐estrogen (E2) and tumor markers in the diagnosis and prognosis of lung cancer. A total of 174 patients, including 117 patients with non–small‐cell lung cancer (NSCLC) and 57 patients with benign pulmonary lesions (BPL), were enrolled. An enzyme‐linked immunosorbent assay was used to detect the expression of E2, carcinoembryonic antigen (CEA), neuron‐specific enolase (NSE), and cytokeratin 19 fragment antigen 21‐1 (CYFRA21‐1) in patients with NSCLC and BPL to analyze the correlation between E2 and CEA, NSE or CYFRA21‐1 expression, and its correlation with clinicopathological features and prognosis. The expression of tumor markers was then examined in different lung cancer cells (A549, H1795, H460, and SK‐MES‐1). The expression of tumor markers was detected by a real‐time reverse transcription‐polymerase chain reaction (RT‐PCR) and Western blot analysis. The expressions of p‐p44/42 mitogen‐activated protein kinase (MAPK) and phospho‐AKT (p‐AKT) were detected by Western blot analysis. The expression levels of E2, CEA, NSE, and CYFRA21‐1 in patients with NSCLC were significantly higher than those in patients with BPL ( P < .05); E2 was positively correlated with tumor markers ( P < .01). Patients with a high expression of E2 and tumor markers showed a poor prognosis ( P < .05). RT‐quantitative PCR and Western blot analysis showed that the expression levels of CEA, NSE, CYFRA21‐1, p‐p44/42 MAPK, and p‐AKT in the E2 group were higher than those in the other groups ( P < .05). These studies indicate that the interaction of E2 and tumor markers can significantly improve the role of tumor markers in the diagnosis and prognosis of lung cancer.